European Commission approves Dovato for treatment of HIV-1 infections in adolescents and adults

recently, http://
The European Commission (EC) has approved Dovato (dolutegravir/lamivudine, DTG/3TC, 50mg/300mg tablets) for the treatment of adolescents over the age of 12 who weigh s40kg and are not known or suspected to be infected with HIV-1 in adolescents and HIV-1Dovato (dolutegravir/lamivudine, DTG/3TC, 50mg/300mg tablets) is a new daily, single-piece, complete two-drug solution (2DR),Dovato is a complete, daily A single-chip two-drug therapy, in clinical studies, is not as effective as dTG-based tridrug regimen (3DR), which was approved in the European Union, marking a key milestone in HIV-1 treatment in the region and will change the first-line treatment model for HIVDovato consists of fixed doses of dolutegravir (DTG) and ramifeddine (3TC), in which DTG is an HIV-integrated enzyme chain transfer inhibitor (INSTI), which blocks the replication of HIV by preventing viral DNA from being integrated into human immune cells (T cells), 3TC is a nucleoside retrovirus (NRTI) and is used in combination with other antiretroviral
drugshttp:// (
)In the United States, Dovato was approved in April by theFDA(http://for the treatment of HIV-1 adults with no known resistance to DTG or 3TC for a history of antiretroviral-free drugs (ARV)Dovato is also the FDA-approved first complete, daily single-chip two-drug program that reduces patient exposure to ARV from the outset, while maintaining the efficacy and high resistance barrier of traditional DTG-based three-drug standard care